Article
A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme.
The Journal of experimental medicine - 11 May 2009
Malynn Barbara A, Ma Averil
Abstract excerpt
Many B cell cancers are characterized in part by the dysregulation of the NF-kappaB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-kappaB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor suppressor protein.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
